Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
ID: 350842Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350842

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-043.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Blueprint Neurotherapeutics Network (BPN) program, which focuses on small molecule drug discovery and development for disorders of the nervous system. This opportunity aims to support neuroscience investigators in advancing their projects into clinical testing, allowing participants to conduct disease-specific assays and collaborate with NIH-funded consultants while retaining intellectual property rights. The program is significant for promoting innovative drug development and ensuring compliance with Good Laboratory Practices. Interested applicants should note that the application period opens in January 2024, with a submission deadline of August 18, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-043-Full-Announcement.html
    PAR-24-043.html
    The Blueprint Neurotherapeutics Network (BPN) at the NIH seeks applications for the small molecule drug discovery and development targeting disorders of the nervous system through its Notice of Funding Opportunity (NOFO) PAR-24-043. This program promotes collaboration between neuroscience researchers and NIH-funded consultants to advance new drug candidates into clinical testing. Projects can begin at either the Discovery or Development stages, with the former focusing on medicinal chemistry optimization and the latter on preclinical safety studies and Phase I trials. Participants retain intellectual property rights and can receive support for crucial activities through a customized Lead Development Team. The program encourages diverse participation and adherence to quality and compliance standards following Good Laboratory Practices. Key dates highlight the application period starting January 2024, with funding contingent on NIH appropriations and merit of applications. Interested applicants should ensure their projects align with the mission of participating NIH Institutes, explore available resources, and engage with NIH personnel prior to submission.
    Similar Opportunities
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) invites applications for the Blueprint Neurotherapeutics Network (BPN), aimed at supporting small businesses in advancing small molecule drug discovery and development for disorders of the nervous system. This funding opportunity, categorized as a Cooperative Agreement under the U44 Small Business Innovation Research (SBIR) program, encourages applicants to conduct disease-specific assays and collaborate with NIH-funded consultants and contract research organizations to facilitate the transition of promising drug candidates from discovery to clinical testing. The program emphasizes compliance with Good Laboratory and Clinical Practices, rigorous study designs, and diversity in research teams, making it a vital resource for small businesses lacking the necessary infrastructure for clinical development. Applications will be accepted starting January 9, 2024, with a closing date of August 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) aimed at advancing small molecule drug discovery and development for disorders of the nervous system. This cooperative agreement invites applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, allowing them to retain intellectual property rights while collaborating with NIH consultants and contract research organizations. The program is designed to facilitate the optimization and testing of drug candidates, adhering to regulatory standards and promoting diversity in research teams, ultimately seeking innovative therapeutic solutions for conditions aligned with NIH institutes such as NINDS, NIA, and NIMH. Interested applicants should prepare comprehensive applications, with key deadlines including a close date of August 18, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), focusing on biologic-based drug discovery and development for disorders of the nervous system. This initiative aims to solicit applications from researchers working on diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, to address various nervous system disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the U44 activity code. Interested applicants should prepare for collaboration and project development, as the estimated award date is set for December 1, 2025. For further details, potential applicants can refer to the NIH website or contact the agency directly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), aimed at advancing biologic-based drug discovery and development for disorders of the nervous system. This initiative seeks applications from researchers focused on developing a variety of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, specifically targeting nervous system and neuromuscular disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the UG3/UH3 activity code. Interested applicants should prepare for collaboration opportunities, as the estimated award date is set for December 1, 2025.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) for Biologics, aimed at supporting biologic-based drug discovery and development for disorders of the nervous system. This initiative invites applications from U.S.-based small businesses to develop diverse therapeutic modalities, including antibodies and gene therapies, with a focus on specific nervous system disorders and a requirement for preliminary data demonstrating efficacy. The program emphasizes a phased, milestone-driven cooperative agreement, facilitating the transition of promising biotherapeutics from lead optimization to first-in-human trials while ensuring regulatory compliance and effective intellectual property management. Applications are due by January 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.